Akari Therapeutics Gets Regulatory Approval To Conduct Phase 2 Study In Paroxysmal Nocturnal Hemoglobinuria
July 13, 2016 at 07:59 AM EDT
Akari Therapeutics (NASDAQ: AKTX) disclosed Wednesday that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has ...